Anaveon appoints Dieter Weinand as Chair of its Board of Directors BASEL, Switzerland, July 30, 2024 (GLOBE NEWSWIRE) -- Anaveon, a clinical stage, immuno-oncology company, today announced the appointment of Dieter Weinand, former Chair and CEO of Bayer...

Anaveon announces presentation of a novel development compound at the 2023 American Association for Cancer Research Annual Meeting BASEL, Switzerland, March 23, 2023 (GLOBE NEWSWIRE) -- Anaveon, a clinical stage, immuno-oncology company, today announced that it will present a poster on ANV600 at the American Association for...

Anaveon announces first patient dosed with ANV419 in a Phase I/II Study of ANV419 in patients with multiple myeloma BASEL, Switzerland, March 16, 2023 (GLOBE NEWSWIRE) -- Anaveon, a clinical stage, immuno-oncology company, today announced the first patient dosed with ANV419 in the OMNIA-2 (ANV419-102) study - a...

Anaveon doses first patient in a Phase I/II Study of ANV419 as monotherapy or in combination with check point inhibitors in patients with advanced melanoma BASEL, Switzerland, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Anaveon, a clinical stage, immuno-oncology company, today announced the first patient has been dosed in the OMNIA-1 study – a Phase I/II study...

Anaveon presents updated data from the Phase I/II study of ANV419 during the ESMO Congress 2022 - ANV419 is well-tolerated at high doses and demonstrates notable safety with strong pharmacodynamic effects and excellent IL-2Rbg selectivity – - A Phase II program of ANV419 has been initiated in...